A protocol for the development of Core Outcome Sets for effectiveness trials and clinical audits in Renal Cell Cancer (R-COS)
| dc.contributor.author | MacLennan, Steven | |
| dc.contributor.author | Winter, Lisa M. | |
| dc.contributor.author | Beyer, Katharina | |
| dc.contributor.author | Lawlor, Ailbhe | |
| dc.contributor.author | Tripathee, Sheela | |
| dc.contributor.author | Dabestani, Saeed | |
| dc.contributor.author | Marconi, Lorenzo | |
| dc.contributor.author | Giles, Rachel H. | |
| dc.contributor.author | Woodward, Rose | |
| dc.contributor.author | Bex, Axel | |
| dc.contributor.author | Zondervan, Patricia | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en | 
| dc.contributor.institution | University of Aberdeen.Academic Urology Unit | en | 
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en | 
| dc.date.accessioned | 2023-10-24T14:26:00Z | |
| dc.date.available | 2023-10-24T14:26:00Z | |
| dc.date.issued | 2023-09 | |
| dc.description | Open access via the Wiley Agreement The data collection for the interview study is funded by NHS Grampian Endowments, and the costs of the interview transcriptions and eDelphi licences will be paid by the Arcobaleno Cancer Trust. Neither funder had any role in the design of the study. All other parts of the study are currently unfunded. The research team is not personally reimbursed for their time and efforts apart from research input by SD, which is financed by Swedish government funding of clinical research (ALF). | en | 
| dc.description.status | Peer reviewed | en | 
| dc.format.extent | 9 | |
| dc.format.extent | 453233 | |
| dc.identifier | 252311975 | |
| dc.identifier | 2fab4c4d-1a8e-4abe-9b44-9a3cc4f54714 | |
| dc.identifier | 37636213 | |
| dc.identifier | 85165590773 | |
| dc.identifier.citation | MacLennan, S, Winter, L M, Beyer, K, Lawlor, A, Tripathee, S, Dabestani, S, Marconi, L, Giles, R H, Woodward, R, Bex, A & Zondervan, P 2023, 'A protocol for the development of Core Outcome Sets for effectiveness trials and clinical audits in Renal Cell Cancer (R-COS)', BJU International, vol. 4, no. 5, pp. 504-512. https://doi.org/10.1002/bco2.266 | en | 
| dc.identifier.doi | 10.1002/bco2.266 | |
| dc.identifier.iss | 5 | en | 
| dc.identifier.issn | 1464-4096 | |
| dc.identifier.other | ORCID: /0000-0002-2691-8421/work/145601380 | |
| dc.identifier.uri | https://hdl.handle.net/2164/21997 | |
| dc.identifier.url | https://www.comet-initiative.org/studies/details/1406. | en | 
| dc.identifier.vol | 4 | en | 
| dc.language.iso | eng | |
| dc.relation.ispartof | BJU International | en | 
| dc.subject | SDG 3 - Good Health and Well-being | en | 
| dc.subject | R Medicine | en | 
| dc.subject.lcc | R | en | 
| dc.title | A protocol for the development of Core Outcome Sets for effectiveness trials and clinical audits in Renal Cell Cancer (R-COS) | en | 
| dc.type | Journal article | en | 
Files
Original bundle
1 - 1 of 1
- Name:
- MacLennan_etal_BJUI_A_Protocol_For_VOR.pdf
- Size:
- 442.61 KB
- Format:
- Adobe Portable Document Format
